OrgaNova TRiCBiO Validates 1,500+ Patient-Derived Organoid Models Across 20+ Cancer Types

OrgaNova TRiCBiO today announced that its biobank has surpassed 1,500 deeply characterized patient-derived organoid (PDO) models, covering more than 20 solid tumor types across its US and China biobanks.

The milestone represents a critical mass of biological material enabling statistically robust drug screening, biomarker discovery, and co-clinical study design at scale. All models are available in both PDO 1.0 and Organoid 2.0 (ALI-PDO™) formats, with full genomic (WES) and transcriptomic (RNA-seq) characterization linked to de-identified patient clinical data.

"1,500 models is not just a number—it's the foundation for a new kind of drug development," said Xingnan Li, PhD, Co-Founder and Chief Scientific Architect. "We now have the breadth and depth to support any oncology program, in any indication, with statistically meaningful data."

The biobank includes models from the US facility in Philadelphia (676+ FFPE blocks, 35 normal tissue types) and the China facility in Nanjing (400+ HCC, 300+ CRC, 200+ RCC, 150+ PDAC, 150+ Breast, 120+ Sarcoma, 100+ NSCLC, 80+ GBM, and more).